{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-105633","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.043713+00:00","generated_at":"2026-05-17T00:54:00.531947+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 (wet AMD) to FDA after Sept 2025 Type A meeting","bullets":["Resubmitted BLA on Nov 3, 2025 for ONS-5010 (LYTENAVA) to treat wet AMD.","Resubmission follows FDA Type A meeting in Sept 2025; aims to resolve CRL issued Aug 2025.","CEO Bob Jahr says resubmission marks 'important step forward' for potential near-term U.S. approval.","Company accelerating commercial efforts in Europe while positioning for U.S. approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-105633","json":"https://secwatch.observer/filing/0001104659-25-105633.json","markdown":"https://secwatch.observer/filing/0001104659-25-105633.md","text":"https://secwatch.observer/filing/0001104659-25-105633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/0001104659-25-105633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/tm2530088d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:54:00.531947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}